Thus, PD-1 expressed on the surface of T cells binds to PD-L1 and exhaustively activates T cells, inducing cytotoxicity and the mechanism of programmed tumor death [16]. These described mechanisms are evident in the responses to neoadjuvant treatment, especially in tumors with HER2 expression [13]. The gene discussed is ERBB2; the disease is neoplasm.